Annual report [Section 13 and 15(d), not S-K Item 405]

STOCKHOLDERS’ EQUITY

v3.26.3
STOCKHOLDERS’ EQUITY
 12 Months Ended
Jun. 30, 2026
Equity [Abstract]  
STOCKHOLDERS’ EQUITY

NOTE 15 - STOCKHOLDERS’ EQUITY

 

During the years ended June 30, 2026 and 2025, the Company issued 37,878 and 58,335 shares of common stock, respectively, to the independent Board of Directors as part of their board compensation. The grant date fair value was $144,000 and $159,000 for each period, and was recorded as compensation expense in the accompanying consolidated financial statements.

 

During the years ended June 30, 2026 and 2025, the Company issued 41,997 and 59,528 shares of common stock to the CEO for his bonus earned in fiscal years 2025 and 2024. The fair market value of the shares was $122,091 and $151,201, respectively.

 

During the year ended June 30, 2026, the Company accrued 44,985 shares of common stock to the CEO for his bonus earned in fiscal years 2026. The fair market value of the shares was $207,828.

 

During the year ended June 30, 2026, the Company accrued 66,571 shares of common stock to one-employee. The fair market value of the shares was $231,000.

 

During the year ended June 30, 2026 and 2025, the Company issued 24,688 and 2,680 shares of common stock to a consultant pursuant to the terms of his consultancy agreement. The grant date fair value of the shares was $91,667 and $8,333 and was recorded as compensation expense in the accompanying consolidated financial statements.

 

During the year ended June 30, 2026, the Company issued 20,000 shares of common stock to employees pursuant to the terms of their employment agreements. The grant date fair value of the shares was $84,400 and was recorded as compensation expense in the accompanying consolidated financial statements.